Jazz Pharmaceuticals’ Epidiolex, a cannabidiol oral solution for treating rare forms of epilepsy, showed mixed results in a Phase 3 trial in Japan. While the trial did not achieve its primary goal of reducing seizure frequency, there were improvements in other areas, and no new safety concerns were identified. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.